Common Contracts
2 similar Development and Exclusive License Option Agreement contracts by Biodelivery Sciences International Inc
EX-10.1 2 d813548dex101.htm DEVELOPMENT AND EXCLUSIVE LICENSE AND OPTION AGREEMENT ***CONFIDENTIAL TREATMENT REQUESTED*** Confidential Treatment Requested by BioDelivery Sciences International, Inc. IRS Employer Identification No. 35-208985...Development and Exclusive License Option Agreement • May 5th, 2020 • New Jersey
THIS DEVELOPMENT AND EXCLUSIVE LICENSE OPTION AGREEMENT (“Agreement”) is made and entered into on October 27, 2014 (“Effective Date”), by and between Evonik Corporation, an Alabama corporation having its principal place of business at 299 Jefferson Road, Parsippany, New Jersey 07054, USA and having an address at 750 Lakeshore Parkway, Birmingham, Alabama, 35211, USA (hereinafter “Evonik”), and BioDelivery Sciences International, Inc., having an address at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina 27607 (hereinafter “Customer”). Customer and Evonik are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED*** Confidential Treatment Requested by BioDelivery Sciences International, Inc. IRS Employer Identification No. 35-208985 Confidential treatment requested with respect to certain portions hereof denoted with “***”...Development and Exclusive License Option Agreement • October 31st, 2014 • Biodelivery Sciences International Inc • Pharmaceutical preparations • New Jersey
THIS DEVELOPMENT AND EXCLUSIVE LICENSE OPTION AGREEMENT (“Agreement”) is made and entered into on October 27, 2014 (“Effective Date”), by and between Evonik Corporation, an Alabama corporation having its principal place of business at 299 Jefferson Road, Parsippany, New Jersey 07054, USA and having an address at 750 Lakeshore Parkway, Birmingham, Alabama, 35211, USA (hereinafter “Evonik”), and BioDelivery Sciences International, Inc., having an address at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina 27607 (hereinafter “Customer”). Customer and Evonik are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
